Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa
International Journal of Nanomedicine · 2024-09 · Volume 19 · 9843-9870
DOI: 10.2147/ijn.s459510 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2024-09. Verfasst von Longfei Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute Chinese Materia Medica China Academy of Chinese Medical Sciences, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Quinazolines, Evodia. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Evodiamine (EVO) is a tryptamine indole alkaloid and the main active ingredient in Evodia rutaecarpa. In recent years, the antitumor, cardioprotective, anti-inflammatory, and anti-Alzheimer's disease effects of EVO have been reported. EVO exerts antitumor effects by inhibiting tumor cell activity and proliferation, blocking the cell cycle, promoting apoptosis and autophagy, and inhibiting the formation of the tumor microvasculature. However, EVO has poor solubility and low bioavailability. Several derivatives with high antitumor activity have been discovered through the structural optimization of EVO, and new drug delivery systems have been developed to improve the solubility and bioavailability of EVO. Current research found that EVO could have toxic effects, such as hepatotoxicity, nephrotoxicity, and cardiac toxicity. This article reviews the pharmacological activity, derivatives, drug delivery systems, toxicity, and pharmacokinetics of EVO and provides research ideas and references for its further in-depth development and clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute Chinese Materia Medica China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
- Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
- National Medical Products Administration Key Laboratory for Research Evaluation of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
- Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, People's Republic of China.
Zitieren
APA
Lin, L., Liu, Y., Tang, R., Ding, S., Lin, H., & Li, H. (2024). Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa. International Journal of Nanomedicine, Volume 19, 9843-9870. https://doi.org/10.2147/ijn.s459510
Vancouver
Lin L, Liu Y, Tang R, Ding S, Lin H, Li H. Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa. International Journal of Nanomedicine. 2024;Volume 19:9843-9870. doi:10.2147/ijn.s459510
BibTeX
@article{Lin2024,
author = {Lin, Longfei and Liu, Yuling and Tang, Ruying and Ding, Shilan and Lin, Hongmei and Li, Hui},
title = {Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa},
journal = {International Journal of Nanomedicine},
year = {2024},
volume = {Volume 19},
pages = {9843--9870},
doi = {10.2147/ijn.s459510}
}
EUVIMED